Budget authority increase for medical product safety is coupled with additional funds for coronavirus countermeasure development and advanced manufacturing.
The US Food and Drug Administration is poised to receive a $103.6m increase in appropriations in fiscal year 2021, along with added coronavirus response funding.
The nearly 5,600-page bill, which passed Congress on 21 December, gives $5.88bn to the agency for FY 2021 activities....
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
